Abstract-A genome screen to identify genes influencing the age at Parkinson disease (PD) onset was completed using 276 families without parkin mutations. Significant evidence of linkage to chromosome 2p near the PARK3 locus (logarithm of odds [lod] ϭ 4.8) was observed. Evidence of linkage was also detected to chromosomes 1q (lod ϭ 3.0) and 8q (lod ϭ 2.6). These data suggest that the genes influencing age at PD onset likely differ from those that contribute to PD susceptibility. NEUROLOGY 2004;62:1616 -1618 Parkinson disease (PD) age at onset has wide variability, ranging anywhere from juvenile to very late (80s to 90s), with an average age at onset of 60 years. Although few families include both juvenile-and late-onset PD, wide disparity in age at onset, even within the same family, has been found. An important question is whether the genes that contribute to PD susceptibility also contribute to age at disease onset or whether different genes are involved. As large multiplex PD datasets are ascertained to identify PD susceptibility genes, it has become possible to directly answer this question. Evidence of linkage for age at onset of PD to chromosomes 1, 6, and 10 1 and chromosomes 2, 9, 20, and 21 2 has been reported.
Materials and methods.
Subjects. Three hundred sixty-six families (n ϭ 788 individuals), consisting of at least one pair of living siblings diagnosed with PD, were recruited through 59 Parkinson Study Group sites located throughout North America. The average age at onset of the PD subjects was 60.9 years, with a range of 18 to 87 years. DNA samples were obtained from all individuals after appropriate written informed consent approved by each individual institution's institutional review board was completed.
As previously described, 3 all study participants completed a rigorous clinical evaluation (including Unified Parkinson's Disease Rating Scale Parts II and III), and the Diagnostic Checklist developed for this project was used to classify participants as either verified PD or nonverified PD. Families with at least two individuals meeting criteria for verified PD were included in the more restrictive primary analyses (Model I), whereas all families were employed in the more inclusive Model II analyses.
Parkin screening. Thirty-one different parkin mutations were previously identified in 39 of the 173 families analyzed, 3 after both direct sequencing and fluorescent dosage analysis were performed. As it has previously been shown that PD patients with parkin mutations have significantly earlier age at onset than those without parkin mutations, 4 all genetic analyses were performed excluding the families with a parkin mutation.
Genome screen. Genotyping was performed using 400 dinucleotide repeat markers from the ABI Prism Linkage Mapping Set (Applied Biosystems, Foster City, CA), as previously described. 3 The average marker heterozygosity was 79%, and the average intermarker spacing was 8.6 cM. Marker allele frequencies were estimated using all 1,576 chromosomes, and the genotypic data were evaluated for Mendelian inheritance of marker alleles and to verify the full sibling relationships among the subjects. Four halfsibling pairs were identified owing to significantly lower than expected sharing of marker alleles identical by descent, and the pedigrees were modified to reflect this.
Statistical analysis. Multipoint, nonparametric linkage analysis was performed using the computer program SOLAR 5 to identify genes contributing to the quantitative trait, age at onset of PD. Linkage analyses were performed using Models I and II.
Results. Sample. Some families could not be used because age at onset was not available for the minimum of two affected individuals. After removing all families with a known parkin mutation, there were 276 families (n ϭ 567 affected individuals) with two or more members having a reported age at PD onset (table 1) .
Analysis of age-at-onset data. The distribution of the age at PD onset in this sample did not significantly deviate from normality, though it was slightly skewed toward early onset (skewness ϭ Ϫ0.77). A high degree of kurtosis may increase the number of false-positive results. 6 The kurtosis of our distribution was relatively low (0.47) and should not substantially increase the false-positive rate. Inclusion of gender as a covariate did not significantly improve the fit of the polygenic model (p ϭ 0.34).
Genome screen. Genome-wide linkage analysis identified several chromosomal regions providing evidence of linkage to the phenotype age at onset of PD symptoms (table 2) . A significant logarithm-of-odds (lod) score of 4.8 was observed on chromosome 2p when only those individuals meeting the stricter disease definition of verified PD were included in the analyses (Model I; figure) . The maximum lod score occurred at marker D2S337, which is within 8 cM of the recently refined PARK3 locus (D2S2113 to D2S1394). 7 As the evidence of linkage in our sample spans 15 cM in this chromosomal region, our region on chromosome 2p overlaps with the PARK3 locus, which was recently implicated in another study mapping genes determining age at onset in PD.
2 Two other regions on chromosomes 1q (lod ϭ 3.0; Model I) and 8q (lod ϭ 2.6; Model II) also produced suggestive evidence of linkage.
Discussion. Strong evidence for a gene contributing to age at onset was detected in our sample on chromosome 2p in a region encompassing the PARK3 locus and that is distinct from our previously reported linkage to chromosome 2q36-37 for PD susceptibility. 8 The PARK3 locus was originally identified as a causative gene in families of German descent, segregating PD in an autosomal dominant pattern, 9 and it is interesting that it appears to act in a different fashion in our sample. Whereas neurodegeneration occurs in all individuals, particularly as they age, the rate at which cells are lost is likely to be quite variable and may not be a linear process. Thus, all individuals, if they were to survive indefinitely, would have sufficient neuronal loss to elicit symptoms of PD; however, because of the variable rate of neurodegeneration, some individuals will never manifest symptoms.
It is intriguing to speculate that mutations that increase the rate of normal neuronal loss may predispose an individual to PD. If these mutations are, in fact, in the same gene, this mechanism may account for the linkage to both PD susceptibility and PD age at onset. A mutation in a gene that dramatically alters the rate of neuronal loss may manifest clinically as a high-penetrance PD mutation, as was observed in several German families. Subtle polymorphisms in the same gene, which may be present in our sample, may still lead to variation in the rate of neurodegeneration and thus alter age at onset of PD. In this instance, other loci must also be contributing to PD susceptibility. Analysis of 14 genes within the PARK3 region did not reveal any potentially pathogenic mutations. 7 Subsequently, suggestive linkage to this chromosomal region was detected in another PD sample, employing the phenotype of age at onset of PD (lod ϭ 2.1). 2 This convergence of linkage evidence from three different studies employing different phenotypes-PD susceptibility and age at PD onsetsuggests that perhaps mutations in a single gene at the PARK3 locus may cause PD and also influence the age at symptom onset.
An important advantage of our study was the identification and exclusion of 39 parkin mutationpositive families prior to the genome screen analyses. Combining samples with differing genetic etiologies may reduce the power to detect genes contributing to the age at onset of PD. The only other regions in our study that exceeded Kruglyak and Lander's threshold for suggestive linkage (lod Ն 2.2) 10 were on chromosomes 1q and 8q. Other studies seeking to identify genes contributing to PD age at onset did not report evidence of linkage to these two regions, 1,2 nor are they within 40 cM of any regions so far implicated in PD susceptibility.
